share_log

HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21

HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21

HC Wainwright&Co.維持在Redhill Biophma的買入,將目標價下調至21美元
Benzinga Real-time News ·  2021/09/15 06:08

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $23 to $21.

HC Wainwright&Co.分析師Raghuram Selvaraju維持Redhill Biophma(納斯達克股票代碼:RDHL)的買入,並將目標價從23美元下調至21美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論